News and Events

Discover our news and events, and information about our project.

Lymphatica Medtech SA is awarded the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its revolutionary product, LymphoDrain. This breakthrough designation represents a significant milestone in the journey toward transforming the treatment landscape for chronic lymphedema.

More info

Prof. Lucia Mazzolai is presenting the LymphoPilot clinical study at the Congress of the European Society of Vascular Medicine (Milan, October 12-14), in a plenary session from the title: “Novelties in lymphedema treatment”

Lymphatica Medtech has a booth: come to visit us!

Our CEO Marco Pisano will be present in Barcelona at the LSI 2023 – Emerging Medtech Summit.

If you are interested in Lymphatica investment opportunity, please contact him for a meeting.

more info

Lymphatica is present at this world-class event at Booth number 10 – come visit us!

Moreover, the Angiology group from CHUV will present our pilot clinical study on October 14 at 11:45 in the Libeccio Hall.

more info

Nanci Govinder, already board member of Lymphatica since 2018, kindly accepted to step-up as Chairperson of the Board. Her extensive experience will be instrumental to ensure the Company focus on strategic matters and to set high governance standards.
Moreover, we welcome John Erb as new Board Member. Previously Chairman of Vascular Solutions Inc. (acquired by Teleflex) and Board Member of CryoCath Technologies (acquired by Medtronic) and of Senox Inc. (acquired by CR Bard), and currently Chairman of Nuwellis, Inc – a global medical device company listed on Nasdaq focused on heart failure products – Mr. John Erb brings a wealth of experience in developing and marketing vascular products internationally.

Prof. Francesco Boccardo presents our clinical trial, while Lymphatica Medtech will be at the booth 13. Come meet us!

more info

The FIT Tech program aims to support entrepreneurs who develop technological projects in the Canton of Vaud and in the Western part of Switzerland, based on a technological innovation that is difficult to imitate and has a high growth potential. It consists in a Loan of up to CHF 400’000, which will be used to accelerate the production, verification, and validation of our product.

more info

Lymphatica Medtech has obtained the support of Innosuisse in the frame of the Swiss Accelerator: a grant CHF 2.5 million to finance the LyBRA project: Lymphatic Bypass for Recirculation of Accumulated fluids in leg lymphedema patients. The project aims at accelerating the time to market for the leg version of the LymphoDrain device.

Lymphatica was selected to participate at the Medtech Innovator East Coast Pitching Event in Baltimore, United States. Lymphatica CEO will present the Company in front of a large cohort of investors, clinicians and expert.

Lymphatica’s CEO will present the Company, its achievements and its growth plans to a relevant cohort of international investors and industry experts.

LSI link

The study, which includes a 2 months implantation period of our device, is being conducted at the Lausanne University Hospital (link). As of today,  the study was completed by 6 upper limb lymphedema patients. While results are still preliminary, they confirm LymphoDrain potential for drastically improving lymphedema patient’s outcome and quality of life.

After in depth audit, the notified body TÜV SÜD granted the renewal of the ISO 13485 certification to Lymphatica Medtech SA. ISO 13485 is the international quality management system standard for medical devices, ensuring the highest medical device quality for patient safety. The certificate can be downloaded here.

After more than 3 years of milestone-based support and coaching, the Swiss Innovation Agency conferred to us the Innosuisse Certificate, certifying that Lymphatica is ready for sustainable investment and sustainable growth.

Innosuisse_Certificate Lymphatica Medtech SA

The Lymphatic Education & Research Network published a very instructive film about Lymphedema:

Not So SWell.

Watch & Share!

Lymphatica’s CEO participated to both the live and live events of the Tech Tour Health 2021, and received the Award as Top Presenting Company In recognition for outstanding Pitching performance throughout the Program and high quality presentation as evaluated by a panel of International Investor Reviewers. The winner will be invited to pitch at the annual Tech Tour Event Future22 in March 2022.

More info at this link

After approval by Swissmedics and by the CER-VD Ethical committee, the LymphoPILOT clinical trial officially started.

For a more details about the study please visit clinical

Lymphatica was selected in the Swiss National Startup Team for the Venture Leaders Medtech 2021 roadshow in Boston – USA.

The company CEO, Marco Pisano, was interviewed here.

Venture Leaders Medtech 2021 is organized by Venturelab and supported by EPF Lausanne, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, Paul Scherrer Institut, Swissnex Boston, University Zurich, Canton of Vaud, and Canton of Zurich.

We are happy to announce that we have closed a 7 digit Series A financing round!
The investment round was led by the High Tech Gründerfonds ( , a large and experienced German VC fund that will accompany on our way forward.
New business angels joined the round, as well as the existing ones, who confirmed the trust in our team.
The EIT Health ( – European Institute of Technology) contributed to the financement, funding development activities to improve the usability and digitalization of our product, LymphoDRAIN.

Together with the cash, we welcome Laurent Duhoux as new member of our Board of Directors. With a proven track record in managing medical technology businesses, Laurent brings to Lymphatica his 20-year experience.

We’ll use the funds to advance in the roadmap to bring LymphoDRAIN to lymphedema patients.

More details in our press release.

Notified body TÜV SÜD granted the ISO 13485 certification to Lymphatica Medtech SA!

ISO 13485 is the international quality management system standard for medical devices.

This certification confirms that Lymphatica operated through highly controlled quality proceses and procedures tailored to optimized the design & development of medical devices.

The certification was awarded following independent audits according to ISO 13485:2016 requirements.

The European Innovation Council of the European Union supports LymphoDrain implant market entry with €1.8 millions grant, via its H2020 SME Instrument program. This additional fund will accelerate the market entry process, supporting pre-series manufacturing and clinical trials.
Being awarded in such a highly competitive selection process is a recognition of excellence of the presented product innovation and of the expected large societal impact.

The EIC Accelerator (former SME Instrument) is a public funding program that funds breakthrough innovation in small businesses. Only the most innovative companies get selected: only 83 projects were funded out of 1765 submitted proposals at the April 2019 call.

More info here.

Lymphatica is selected among the 10 Venture Leaders for a fundraising campaign in China
Venture Leaders China 2019

We will present our latest results at the International Lymphatic Framework Conference in Chicago (13-15 June, 2019). Please come and visit us!

Lymphatica Medtech was selected between the presenting companies at the 28th Medtech Investing Europe Conference

Lymphatica participates to a round table to discuss about the future of lymphedema care

Congress program

Lymphatica was selected to participate at the 12th edition of the European Venture Contest Final – Europe’s leading network and investment event for high-growth technological start-ups, venture capital investors and technological corporations

more info

Discover our technology

LymphoDrain™, is a permanent implant designed to actively drain the lymph that physiologically leaks in the interstitial space, but it is not effectively drained in lymphedema patients.